Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery

Clinical Immunology

Volumn 102, Issue 2, 2002, Pages 169-178

  Galizia, Gennaro ^a   Orditura, Michele ^a   Romano, Ciro ^a   Lieto, Eva ^a   Castellano, Paolo ^a   Pelosio, Luigi ^a   Imperatore, Vincenzo ^a   Catalano, Giuseppe ^a   Pignatelli, Carlo ^a   De Vita, Ferdinando ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Colon cancer; Prognosis; Serum IL 10; Serum IL 6; Surgery

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6;

ACCURACY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COLON CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036176551     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5163     Document Type: Article

References (24)

1. Escape from host-antitumor immunity
2. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via 'downregulation of class II major histocompatibility complex expression
3. Human interleukin- 10 can directly inhibit T cell growth
4. IL-10, T-lymphocyte inhibitor of human blood cell production of IL- 1 and tumor necrosis factor
5. Interleukin- 10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck
6. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors
7. Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions
8. Production of interleukin- 10 by human bronchogenic carcinoma
9. Human non-small cell lung cancer cells express a type 2 cytokine pattern
10. Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor
11. Increased interleukin- 10 serum levels in patients with solid tumors
12. Serum levels of interleukin-10 and interleukin- 6 in patients with lung cancer
13. Serum interleukin- 10 levels in patients with advanced gastrointestinal malignancies
14. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
15. Serum interleukin-10 but not interleukin- 6 is related to clinical outcome in patients with resectable hepatocellular carcinoma
16. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias
17. Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma
18. Interleukin- 6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer
19. Serum interleukin 6 as a prognostic factor in patients with prostate cancer
20. Interleukin- 6 serum level correlates with survival in advanced gastrointestinal cancel patients but is not an independent prognostic indicator
21. The host-tumor immune conflict: From immunosuppression to resistance and destruction
22. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
23. The role of cytokines in cancer
24. The importance of IL-6 protein expression in primary human renal cell carcinoma: An immunohistochemical study